QURE has doubled in a month, insiders are cashing out at pace, and the Street is scrambling to reprice — the tension this week is between a genuine catalyst and the question of who's left to buy.
The insider activity is the most striking data point. CEO Matthew Kapusta sold over 167,000 shares across June 17 and 18, generating roughly $7.6 million in proceeds at prices between $42 and $50. A director, Madhavan Balachandran, sold a further 11,685 shares across the same two days. The net 90-day insider position is technically positive at roughly 324,000 shares and $12.8 million — but that reflects earlier accumulation, not this week. The concentrated CEO selling, right at the top of an 82% weekly surge, is hard to dismiss as routine diversification.
The Street moved fast when the catalyst hit. Barclays upgraded to Overweight and lifted its target from $25 to $65 on June 18 — a bullish pivot from a firm that had been sitting on the sidelines. Goldman Sachs kept its Neutral but raised its target from $14 to $46. Leerink Partners and RBC Capital both maintained Outperform ratings and lifted targets to $70 and $65 respectively. The consensus mean price target now sits around $51, which at the current price of $49 implies very limited near-term upside on a blended basis — though bulls at Leerink and RBC see another 30-40% from here. The analyst recommendation differential factor ranks in the 98th percentile, signalling the Street is unusually aligned on the bullish side relative to the broader universe. The bear case remains structural: no revenue, AMT-130's Huntington's disease programme has faced repeated delays, and the company burns cash with no near-term commercial inflection on the horizon.
Short interest has eased since the previous note, but remains elevated. SI slipped about 2.5% on the week to 16.3% of the free float — roughly 10.1 million shares — compared with 17.2% reported seven days ago. That's a modest cover, not a capitulation. The month-on-month picture is more telling: shorts are down 15% from their May highs, suggesting some bears were already exiting before this week's spike. The borrow market is not constraining new short sellers. Availability is running at 486%, meaning nearly five shares remain available in the lending pool for every one already borrowed — loose by any measure, and well above the 52-week floor of 145%. Cost to borrow at 0.66% is low, despite rising about 52% on the week. Shorts who want to press the rally face no structural friction.
Options positioning tells the most striking positioning story of the week. The put/call ratio has collapsed to 0.14, more than two and a half standard deviations below its 20-day average of 0.17. That is close to the 52-week low of 0.12 — the most call-heavy options skew of the past year. Traders are piling into upside rather than protecting against downside. When a stock has already doubled and the PCR is near its annual floor, that combination warrants attention. Peers show a broadly positive week too: BHVN gained 22%, FDMT rose 26%, and RYTM added 18% — so QURE is running with a risk-on gene therapy tape rather than against it.
The next earnings print is July 31. That event's shape will matter: the May 5 print produced a 10% one-day gain that extended to 41% over five days — the kind of follow-through that reinforces momentum. With insider selling accelerating at these levels, borrow conditions loose enough to absorb new short interest, and options skew at a near-annual extreme for calls, the setup into that date is one where the amplitude of any move — in either direction — looks amplified.
See the live data behind this article on ORTEX.
Open QURE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
